profit from every PLN 100 of sales.
PLN 0PLN 100
NEUCA
PLN 690.00-0.14% today
-15.6% in 1 year
1-year low PLN 655.001-year high PLN 850.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay PLN 20.06 for every PLN 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What NEUCA sold, what it kept, and what it did with the cash.
Sales went from PLN 11.2 billion in 2022 to PLN 13.6 billion in 2025, with PLN 156 million of profit last year.
SalesProfit
NEUCA handed back 38% of the cash it generated last year.
Buybacks PLN 88MPLN 72M
Free cash flow 2025PLN 424M
Bought back its own sharesPLN 88M
Paid as dividendsPLN 72M
Cash vs. debtPLN 138M vs. PLN 502M
NEUCA vs. similar companies
NEUCA grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from PLN 100 of sales | Sales growth a year | Price per PLN 1 of profit |
|---|---|---|---|
| NEUCA | 20.1× · Fair price | ||
 McKesson | 26.2× · Fair price | ||
 Cencora | 43.0× · Expensive | ||
 Cardinal Health | 41.1× · Expensive | ||
 Sigma Healthcare | 63.4× · Very expensive |
AI analysis
An AI analyst reads NEUCA's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of PLN | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 11,232 | 11,813 | 12,612 | 13,644 | |
| 1,126 | 1,307 | 1,441 | 1,558 | |
| 256 | 271 | 304 | 296 | |
| 350 | 400 | 418 | 393 | |
| 137 | 146 | 154 | 156 | |
| 30.00 | 32.48 | 34.01 | – | |
| 10.0% | 11.1% | 11.4% | 11.4% | |
| 2.3% | 2.3% | 2.4% | 2.2% | |
| 1.2% | 1.2% | 1.2% | 1.1% |
Balance sheet
| In millions of PLN | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4,760 | 5,175 | 5,510 | 6,242 |
| Cash | 208 | 105 | 110 | 138 |
| Total debt | 378 | 369 | 449 | 502 |
| Total liabilities | 3,824 | 4,118 | 4,098 | 4,973 |
| 883 | 990 | 1,139 | 1,058 | |
| 5 | 5 | 5 | – | |
| 16.2% | 17.0% | 15.2% | 13.8% | |
| 15.5% | 14.8% | 13.5% | 14.7% |
Cash flow
| In millions of PLN | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 336 | 288 | 63 | 549 | |
| 81 | 94 | 93 | 125 | |
| 254 | 194 | -30 | 424 | |
| Dividends paid | 52 | 58 | 66 | 72 |
| 73 | 14 | 7 | 88 | |
| 11 | 10 | 19 | 15 |
Valuation
- 20.1×
- –
- –
- 3.1×
- 0.2×
- 7.4×
- 8.9×
- 13.6%
- 5.0%
- 2.3%
Profitability
- 11.4%
- 2.2%
- 1.1%
- –
- 13.8%
- 15.5%
- –
- –
- –
- –
Growth
- +6.7%
- –
- –
- –
- −0.7%
Financial health
- 0.9×
- 0.47
- –
- 4.4×
- 0.89
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 16%of 959
Bottom 31%of 888
Top 35%of 599
Bottom 35%of 889
Top 5%of 987
2.3%of the share price, paid each year
On $1,000 invested$23a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
46.3% of its profit
Room to growStretchedMore than it earns: 17.0%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
61Pass
Benjamin Graham
50No pass
Philip Fisher
44No pass
Peter Lynch
45No pass
Joel Greenblatt
43No pass
Charlie Munger
44No pass
Terry Smith
44No pass
Questions about NEUCA
Is NEUCA a good stock to buy?
A business with weak numbers at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the NEUCA AI analysis
What does NEUCA do?
NEUCA is a leading Polish pharmaceutical wholesaler with manufacturing and medical-services arms. It is in Medical Distribution.
Does NEUCA pay a dividend?
Yes. At today's price the dividend is 2.3% a year, about 46% of its yearly profit. In 2025 it paid out PLN 72.0 million in dividends.
Is NEUCA stock halal?
Yes. NEUCA passes our halal screen: its business is permitted and its debt is 16% of its market value, under the 30% limit. How we check
How has NEUCA stock done over the past year?
Down 15.6% over the past twelve months, to PLN 690.00. It traded between PLN 655.00 and PLN 850.00 and is 18.8% below its high.
Who are NEUCA's competitors?
The largest listed companies in the same industry are McKesson, Cencora, Cardinal Health and Sigma Healthcare. The peers table on this page compares their profit, growth and price with NEUCA's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.